Placeholder Banner

BIO Files Amicus Brief on Case Addressing Unfairness or Imbalance in Post-Grant Proceedings at PTO (U.S. Court of Appeals for the Federal Circuit)

April 9, 2018

BIO and the Pharmaceutical Research and Manufacturers of America (PhRMA) filed an amicus brief in Virnetx Inc. v. The Mangrove Partners Master Fund, Ltd., Apple Inc., and Black Swamp IP, LLC at the U.S. Court of Appeals for the Federal Circuit.

Biotechnology and pharmaceutical businesses and entrepreneurs rely on the validity and enforceability of their patents to develop innovative products to address unmet medical needs, increase crop yields, and fight disease, hunger, and pollution. Without the promise of effective and predictable patent rights, the investment in the development of these products would be far more difficult – if not impossible – to undertake.

BIO and PhRMA are interested in the outcome of the case because they have a strong interest in preventing unfairness or imbalance in post-grant proceedings at the Patent and Trademark Office (PTO), including instances where such proceedings are improperly instituted or multiple parties improperly joined to the detriment of the patent owner. BIO and PhRMA urge the court to hold that non-compliance with the one-year time limit for properly filing an IPR petition set forth in 35 U.S.C. § 315(b) bars a petitioner from being joined to an ongoing IPR under 35 U.S.C. § 315(c).

Related Resources
BIO PhRMA Brief ECF 62
Discover More
The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge the Federal Trade Commission (FTC) lawsuit to block the acquisition of Horizon by Amgen. The amicus brief was filed in the U.S. District Court, Northern…
BIO has filed an amicus brief in U.S. ex rel. Scutte v. SuperValu Inc., which addresses the issue of the intent requirement under the False Claims Act (FCA). Specifically, BIO urges the Court to uphold the view that a firm does not…
The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge a District Court’s unprecedented ruling (related to a single drug known as mifepristone) that would create regulatory barriers and potentially upend FDA’s…